Name：Ying Li

Position：Lecturer

E-mail：li.ying@szu.edu.cn

Personal Statement:

Dr. Ying Li received her Ph.D. from Shenyang Pharmaceutical University in 2006, and then joined the the Shenzhen Research Institute of Hong Kong Polytechnic University for postdoctoral training. In 2012, Dr. Li joined the Graduate School at Shenzhen of Tsinghua University as a Lecturer. Dr. Li  obtained the title of Senior Pharmaceutical Engineer of Guangdong Province in 2010 and then has taken the position of Lecturer in the Pharmacy Department of Shenzhen University since 2014.

Dr. Li has been engaged in improving the oral absorption of insoluble drugs, the application of supercritical fluid preparation technology and nanoporous materials. She has completed a National Natural Science Foundation of China grant and many basic research projects awarded by Shenzhen Science and Technology Innovation Commission. Dr. Li has published many papers in high impact academic journals such as Theranostics, International Journal of Biological Macromolecules, Materials and Design, Nanomedicine, etc. as a correspondent or co-corresponding author..

Research Interests:

Drug delivery system

Nanomaterials

Biomimetic targeting technolog

Research Projects:

1. NSFC (China) Project (81102824):  01/01/2012 to 12/31/2015  ￥220,000

2. the General Project of Shenzhen Stable Support Program

 (NO 20200811223235001):  01/0101/2021 to 07/31/2023 ￥300,000

3. Shenzhen Science and Technology Innovation Commission grant (NO JCYJ20150410112709457):  10/15/2015 to 04/15/2018 ￥300,000

Selected Peer-reviewed Publications:

1. Hu XL^#, Xiong W^#,Liu XK, Wang Sh, Chen QL, Gao K Q, Li CY, LiY*. Biomimetic, folic acid-modified mesoporous silica nanoparticles with "stealth" and "homing" capabilities for tumor therapy. Materials & Design. 2024, 241: 112899-112910.

2. Zhang Q^#, Li Y^#, Wang Sh, Gu DH, Zhang CH, Xu SH, Fang XL, Li CY, Wu HQ, Xiong W*. Chitosan-based oral nanoparticles as an efficient platform for kidney-targeted drug delivery in the treatment of renal fibrosis. International Journal of Biological Macromolecules. 2024, 256: 128315-128325.

3. Li Y^#, Deng GX^#, Hu XL, Li CY, Wang XD, Zhu QC, Zheng K, Xiong W*, Wu HQ*. Recent advances in mesoporous silica nanoparticle-based targeted drug delivery systems for cancer therapy, Nanomedicine. 2022, 17(18): 1253-1279.

4. Li Y, Miao YQ, Chen MS, Chen X, Li FF, Zhang XX*, Gan Y. Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy, Theranostics. 2020, 10(8): 3722-3736.

5. Li Y, He ZD, Zhen QE, Hu CS, Lai WF. Hydroxypropyl-β-cyclodextrin for delivery of baicalin via inclusion complexation by supercritical fluid encapsulation, Molecules. 2018, 23: 1169-1183.